# A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma

> **NCT03184987** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 111 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FF/UMEC/VI 100/62.5/25 mcg
- **DRUG:** FF/UMEC/VI 200/62.5/25 mcg
- **DRUG:** Salbutamol
- **OTHER:** ACQ-7

## Key facts

- **NCT ID:** NCT03184987
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-22
- **Primary completion:** 2019-06-25
- **Final completion:** 2019-06-25
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2020-05-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03184987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03184987, "A Long-term Safety Study of Fixed Dose Combination Therapy Fluticasone Furoate/Umeclidinium Bromide/Vilanterol Trifenatate in Japanese Subjects With Asthma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03184987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*